Table of Content

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Market Estimates
Geographic Breakdown
Analyst’s Credentials
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
DNA Damage
Sources of DNA Damage
DNA Repair Mechanism
Base Excision Repair and Nucleotide Excision Repair
Repair of Double-Strand Breaks
Nucleotide Excision Repair
Mismatch Repair
Homologous Recombination (HR)
Non-Homologous End Joining (NHEJ)
Alternative End Joining
Targets for Cancer Therapy
DNA Damage Response for Cancer Chemotherapy
Targeting PARP-1
Targeting APE 1
Targeting XRCC 1
Targeting DNA-PKcs
Targeting Ligases
Targeting PI-3 kinase
Chapter 4 Market Breakdown by Technology Type
Poly(ADP-Ribose) Polymerase Inhibitors
Structure and Function of PARP Inhibitors
Use of PARP Inhibitors in Treatment
FDA-approved PARP Inhibitors for Use in Cancer Treatment
PARP Inhibitors in Clinical Trials
Chapter 5 Market Breakdown by Application
Ovarian Cancer
Epidemiology of Ovarian Cancer
Risk Factors for Ovarian Cancer
Breast Cancer
Risk Factors for Breast Cancer
Signs and Symptoms
Treatment
Challenges
Global Impact
Chapter 6 Market Breakdown by Region
Market Overview and Discussion
Rise of DNA Repair Cases by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 R&D in the Pharmaceutical Industry
Healthcare Expenditures
Continued Emphasis on R&D Activities
Trends in the Pharmaceutical Industry
Factors Influencing Spending for R&D
Trends in R&D Spending and New Drug Development
R&D Spending
New Drug Development
Approvals of New Drugs
Trends in Recent Drug Spending by Therapeutic Class
Types of New Drug Development
Factors Influencing R&D Spending
Projected Revenues
Revenues as Funding for R&D
New Drug Costs in R&D
Chapter 8 DNA Repair Inhibitors on SARS-CoV-2
Biological Structure of SARS-CoV-2
Viral Infection Induces DNA Damage
Federal Funding for the Development of COVID-19 Vaccines
Chapter 9 Company Profiles
ABBVIE INC.
AMGEN INC.
ABBOTT LABORATORIES
ASTRAZENECA PLC
BAYER AG
BRISTOL-MYERS SQUIBB CO.
ELI LILLY
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
JOHNSON & JOHNSON
MERCK & CO., INC.
MERCK KGAA
NOVARTIS AG
PFIZER INC.
SANOFI S.A.



List of Figures


Summary Figure : Global Market for DNA Repair Drugs, by Type, 2020-2026
Figure 1 : Pathway of Cellular DNA Damage and Repair
Figure 2 : Chemical Structural of DNA Nucleotides
Figure 3 : Direct Repair of Thymine Dimers
Figure 4 : Repair of O6 - Methylguanine
Figure 5 : Short-Patch and Long-Patch BER Pathways
Figure 6 : Mechanism of NHEJ Repair of Double-Strand Breaks in DNA
Figure 7 : Characteristics-Based Excision Repair, Nucleotide Excision Repair and Mismatch Repair
Figure 8 : DNA Double Stand Base Repair Pathway
Figure 9 : Environmental Gear Selection
Figure 10 : Global Market for DNA Repair Drugs, by Type, 2020-2026
Figure 11 : Structure Schematic of PARP Molecule
Figure 12 : Interaction Between PARP and HR
Figure 13 : Chemical Structure Formula of PARP Inhibitors
Figure 14 : Global Market for DNA Repair Drugs, by Application, 2020-2026
Figure 15 : Incidence, Mortality and Prevalence of Ovarian Cancer
Figure 16 : Ovarian Cancer by Region and Gender
Figure 17 : Incidence, Mortality and Prevalence of Breast Cancer
Figure 18 : Breast Cancer, by Region and Gender
Figure 19 : Global Market Shares for DNA Repair Drugs, by Region, 2020
Figure 20 : North American Market Shares for DNA Repair Drugs, by Country, 2020
Figure 21 : European Market Shares for DNA Repair Drugs, by Country, 2020
Figure 22 : Asia-Pacific Market Shares for DNA Repair Drugs, by Country, 2020
Figure 23 : R&D Intensities for Publicly Traded U.S. Companies
Figure 24 : Annual Approvals of New Drugs by FDA
Figure 25 : New Drug Approvals
Figure 26 : U.S. Retail Drug Spending by Therapeutic Area
Figure 27 : BARDA Funding for COVID-19 Vaccine

List of Tables


Summary Table : Global Market for DNA Repair Drugs, by Type, Through 2026
Table 1 : Global Market for DNA Repair Drugs, by Type, Through 2026
Table 2 : FDA-Approved PARP Inhibitors
Table 3 : Global Market for DNA Repair Drugs, by Application, Through 2026
Table 4 : Global Market for DNA Repair Drugs, by Region, Through 2026
Table 5 : North American Market for DNA Repair Drugs, by Country, Through 2026
Table 6 : European Market for DNA Repair Drugs, by Country, Through 2026
Table 7 : Asia-Pacific Market for DNA Repair Drugs, by Country, Through 2026
Table 8 : Rest of the World Market for DNA Repair Drugs, Through 2026
Table 9 : AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
Table 10 : AbbVie: Oncology Pharmaceutical Products Portfolio
Table 11 : AbbVie: Marketed Products
Table 12 : AbbVie: Key Developments, 2021
Table 13 : Allergan PLC: Marketed Products
Table 14 : Amgen: Oncology Pharmaceutical Products Portfolio
Table 15 : AstraZeneca: Oncology Pharmaceutical Products Portfolio
Table 16 : AstraZeneca: Oncology Pharmaceutical Revenue, 2018-2020
Table 17 : Bayer AG: Marketed Products
Table 18 : Bayer AG: Oncology Pharmaceutical Products Portfolio
Table 19 : Bayer AG: Oncology Pharmaceutical Revenue, 2018-2020
Table 20 : Bristol-Myers Squibb: Oncology Pharmaceutical Products Portfolio
Table 21 : Bristol-Myers Squibb: Oncology Pharmaceutical Revenue, 2018-2020
Table 22 : Eli Lilly and Co.: Marketed Products
Table 23 : Eli Lilly and Co.: Oncology Pharmaceutical Products Portfolio
Table 24 : Eli Lilly and Co.: Oncology Pharmaceutical Revenue, 2018-2020
Table 25 : Roche: Oncology Pharmaceutical Products Portfolio
Table 26 : Roche: Oncology Pharmaceutical Revenue, 2018-2020
Table 27 : Johnson & Johnson: Oncology Pharmaceutical Products Portfolio
Table 28 : Johnson & Johnson: Oncology Pharmaceutical Revenue, 2018-2020
Table 29 : Merck & Co., Inc.: Marketed Products
Table 30 : Merck & Co., Inc.: Oncology Pharmaceutical Products Portfolio
Table 31 : Merck & Co., Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 32 : Merck KGaA: Marketed Products
Table 33 : Novartis: Oncology Pharmaceutical Products Portfolio
Table 34 : Novartis: Oncology Pharmaceutical Revenue, 2018-2020
Table 35 : Pfizer Inc.: Oncology Pharmaceutical Products Portfolio
Table 36 : Pfizer Inc.: Marketed Products
Table 37 : Pfizer Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 38 : Sanofi: Oncology Pharmaceutical Products Portfolio
Table 39 : Sanofi: Oncology Pharmaceutical Revenue, 2018-2020